Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Treasury Shares (2016 - 2026)

Ani Pharmaceuticals' Treasury Shares history spans 12 years, with the latest figure at $33.2 million for Q4 2025.

  • On a quarterly basis, Treasury Shares rose 58.03% to $33.2 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.2 million, a 58.03% increase, with the full-year FY2025 number at $33.2 million, up 58.03% from a year prior.
  • Treasury Shares hit $621296.0 in Q4 2025 for Ani Pharmaceuticals, up from $613972.0 in the prior quarter.
  • Over the last five years, Treasury Shares for ANIP hit a ceiling of $1.5 million in Q4 2024 and a floor of $83000.0 in Q3 2021.
  • Historically, Treasury Shares has averaged $581515.2 across 5 years, with a median of $503000.0 in 2024.
  • Biggest five-year swings in Treasury Shares: crashed 50.0% in 2021 and later soared 256.82% in 2025.
  • Tracing ANIP's Treasury Shares over 5 years: stood at $3.1 million in 2021, then surged by 62.49% to $5.1 million in 2022, then soared by 97.9% to $10.1 million in 2023, then skyrocketed by 108.71% to $21.0 million in 2024, then surged by 58.03% to $33.2 million in 2025.
  • Business Quant data shows Treasury Shares for ANIP at $33.2 million in Q4 2025, $32.6 million in Q3 2025, and $31.6 million in Q2 2025.